A Perth-based biotechnology company is set to begin phase one clinical trials of a cancer drug for the treatment of motor neurone disease.
Subscribe now for unlimited access.
$0/
(min cost $0)
or signup to continue reading
PharmAust Ltd has received more than $880,000 from the Fight MND campaign for the trial on monepantel or MPL.
Monepantel has previously shown it can influence cancers and have some effect on the progress of MND in preclinical investigations.
The drug trial, at centres in Melbourne and Sydney, is scheduled to start in June after final technical and regulatory approvals.
A special tablet has also been developed with a design and shape to make it easier for MND patients to swallow.
PharmAust said the phase one trial would test the safety and tolerability of MPL in patients living with MND and look for signs that it could slow progression of the disease.
Data from the trial would determine if the drug proceeded to larger phase two studies.
"We are pleased with the development of our phase one MPL trial for MND, and look forward to commencing recruitment," Chief Scientific Officer Richard Mollard said.
Australian Associated Press
